Literature DB >> 19496740

Use of single-pill combination therapy in the evolving paradigm of hypertension management.

David A Calhoun.   

Abstract

The use of antihypertensive therapy is an evolving paradigm. Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clinical guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clinicians to use combination therapy as first-line treatment in selected patients. Single-pill combinations of two complementary antihypertensive medications offer benefits beyond those of separate administration of the individual component agents, providing a simpler medication regimen that is effective and well tolerated while enhancing patient adherence to therapy. In the future, there may be single-pill combinations of three antihypertensive drugs to further enhance BP control rates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496740     DOI: 10.1517/14656560902980210

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

Review 1.  Role of olmesartan in combination therapy in blood pressure control and vascular function.

Authors:  Carlos M Ferrario; Ronald D Smith
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

2.  Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.

Authors:  Dean J Kereiakes; Steven G Chrysant; Joseph L Izzo; Thomas Littlejohn; Suzanne Oparil; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-01-24       Impact factor: 3.738

3.  Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.

Authors:  Andrew J Lewin; Joseph L Izzo; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

4.  Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Authors:  Dean J Kereiakes; Steven G Chrysant; Joseph L Izzo; Thomas Littlejohn; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  Cardiovasc Diabetol       Date:  2012-10-30       Impact factor: 9.951

5.  Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.

Authors:  Natalie Timme; Youjia Han; Shuai Liu; Hailemichael O Yosief; Heathcliff Dorado García; Yi Bei; Filippos Klironomos; Ian C MacArthur; Annabell Szymansky; Jennifer von Stebut; Victor Bardinet; Constantin Dohna; Annette Künkele; Jana Rolff; Patrick Hundsdörfer; Andrej Lissat; Georg Seifert; Angelika Eggert; Johannes H Schulte; Wei Zhang; Anton G Henssen
Journal:  Transl Oncol       Date:  2019-12-21       Impact factor: 4.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.